Lonn Ryonn Pharma

Lonn Ryonn Pharma is a clinical-stage biotechnology company based in Shenzhen, China, specializing in the research, development, and manufacturing of therapeutic monoclonal antibodies and antibody-drug conjugates (ADCs). Established in 2010 by Dr. Simon Kwong, the company has developed a robust pipeline focusing on immunological disorders, oncology, and infectious diseases. Its lead candidate, Suciraslimab (SM03), is a first-in-target anti-CD22 antibody being co-developed with SinoMab Bioscience and is currently in Phase 3 trials for rheumatoid arthritis. Supported by high-capacity GMP manufacturing facilities and a strategic alliance with Synermore Biologics, Lonn Ryonn is a key player in the development of next-generation biologics and biosimilars in the Greater China region.